Neogenomics Stock

Neogenomics P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Neogenomics (NEO) as of Jul 25, 2026 is -67.61. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -43.26 — a change of 56.30% (lower).

P/FCF

-67.61

YoY

56.30%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Neogenomics is 2026 -67.61 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Neogenomics was 2025 -43.26 . It decreases by 56.30% lower compared to the previous year.
Access this data via the Eulerpool API

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Neogenomics is -67.61 in 2026.

Access this data via the Eulerpool API

Valuation — Neogenomics

All Key Metrics — Neogenomics